Adc Therapeutics SA is a biotechnology business based in the US. Adc Therapeutics shares (ADCT) are listed on the NYSE and all prices are listed in US Dollars. Adc Therapeutics employs 312 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Adc Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ADCT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Adc Therapeutics stock price (NYSE: ADCT)
Use our graph to track the performance of ADCT stocks over time.Adc Therapeutics shares at a glance
Latest market close | $8.54 |
---|---|
52-week range | $5.52 - $32.00 |
50-day moving average | $8.25 |
200-day moving average | $17.17 |
Wall St. target price | $29.33 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.54 |
Buy Adc Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Adc Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Adc Therapeutics price performance over time
Historical closes compared with the close of $8.54 from 2022-07-01
1 week (2022-06-27) | 6.48% |
---|---|
1 month (2022-06-03) | 18.61% |
3 months (2022-04-05) | -42.02% |
6 months (2022-01-05) | -56.41% |
1 year (2021-07-02) | -64.68% |
---|---|
2 years (2020-07-02) | -83.27% |
3 years (2019-07-01) | N/A |
5 years (2017-07-01) | N/A |
Adc Therapeutics financials
Revenue TTM | $80.4 million |
---|---|
Gross profit TTM | $-125,478,000 |
Return on assets TTM | -27.72% |
Return on equity TTM | -84.74% |
Profit margin | -242.69% |
Book value | $2.12 |
Market capitalisation | $656 million |
TTM: trailing 12 months
Adc Therapeutics share dividends
We're not expecting Adc Therapeutics to pay a dividend over the next 12 months.
Adc Therapeutics share price volatility
Over the last 12 months, Adc Therapeutics's shares have ranged in value from as little as $5.52 up to $32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Adc Therapeutics's is 1.9545. This would suggest that Adc Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Adc Therapeutics overview
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B. V. , Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited.
Adc Therapeutics in the news
ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents
HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications
Frequently asked questions
What percentage of Adc Therapeutics is owned by insiders or institutions?Currently 52.345% of Adc Therapeutics shares are held by insiders and 45.829% by institutions. How many people work for Adc Therapeutics?
Latest data suggests 312 work at Adc Therapeutics. When does the fiscal year end for Adc Therapeutics?
Adc Therapeutics's fiscal year ends in September. Where is Adc Therapeutics based?
Adc Therapeutics's address is: Biopole, Epalinges, Switzerland, 1066 What is Adc Therapeutics's ISIN number?
Adc Therapeutics's international securities identification number is: CH0499880968
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert